Evidence map›Paper›PMID 36174875›Full record

ReviewBiochimica et biophysica acta. Molecular basis of disease2022

Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health.

Elena Lo Presti, Domenico Nuzzo, Wael Al Mahmeed, Khalid Al-Rasadi, Kamila Al-Alawi, Maciej Banach, Yajnavalka Banerjee, Antonio Ceriello, Mustafa Cesur, Francesco Cosentino and 18 more

Open access · greenAbstract readReview
In one paragraph

Review in Biochimica et biophysica acta. Molecular basis of disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Post-COVID-19 inflammation and sarcopenia in obese diabetic dialysis patients.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. New-Onset Diabetes Mellitus in COVID-19: A Scoping Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 20 institutions in 17 countries.

Elena Lo PrestiInstitute for Biomedical Research and Innovation, National Research Council, Palermo, Italy. Electronic address: elena.lopresti@cnr.it.
Domenico NuzzoInstitute for Biomedical Research and Innovation, National Research Council, Palermo, Italy.
Wael Al MahmeedHeart and Vascular Institute, Cleveland Clinic, Abu Dhabi, United Arab Emirates.
Khalid Al-RasadiMedical Research Center, Sultan Qaboos University, Muscat, Oman.
Kamila Al-AlawiDepartment of Training and Studies, Royal Hospital, Ministry of Health, Muscat, Oman.
Maciej BanachDepartment of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Poland; Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland; Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland.
Yajnavalka BanerjeeDepartment of Biochemistry, Mohamed Bin Rashid University, Dubai, United Arab Emirates.
Antonio CerielloIRCCS MultiMedica, Milan, Italy.
Mustafa CesurClinic of Endocrinology, Ankara Güven Hospital, Ankara, Turkey.
Francesco CosentinoUnit of Cardiology, Karolinska Institute and Karolinska University Hospital, University of Stockholm, Sweden.
Alberto FirenzeUnit of Research and International Cooperation, University Hospital of Palermo, Italy.
Massimo GaliaDepartment of Biomedicine, Neurosciences and Advanced Diagnostics (Bind), University of Palermo, Italy.
Su-Yen GohDepartment of Endocrinology, Singapore General Hospital, Singapore.
Andrej JanezDepartment of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, Slovenia.
Sanjay KalraDepartment of Endocrinology, Bharti Hospital & BRIDE, Karnal, India.
Nitin KapoorDepartment of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, India; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Peter KemplerDepartment of Medicine and Oncology, Semmelweis University, Budapest, Hungary.
Nader LessanThe Research Institute, Imperial College London Diabetes Centre, Abu Dhabi, United Arab Emirates.
Paulo LotufoCenter for Clinical and Epidemiological Research, University Hospital, University of São Paulo, Brazil.
Nikolaos PapanasDiabetes Center, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Greece.
Ali A RizviDepartment of Medicine, University of Central Florida College of Medicine, Orlando, FL, USA.
Amirhossein SahebkarApplied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Raul D SantosHeart Institute (InCor) University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil; Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
Anca P StoianFaculty of Medicine, Diabetes, Nutrition and Metabolic Diseases, Carol Davila University, Bucharest, Romania.
Peter P TothCicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Vijay ViswanathanDiabetes Research Centre, Chennai, India.
Manfredi RizzoDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), University of Palermo, Italy. Electronic address: manfredi.rizzo@unipa.it.
CArdiometabolic Panel of International experts on Syndemic COvid-19 (CAPISCO)
Institute for Biomedical Research and Innovation · ITUniversity of Palermo · ITBaker Heart and Diabetes Institute · AUBharti Hospital · INCarol Davila University of Medicine and Pharmacy · RODemocritus University of Thrace · GRDepartment of Health · ESGüven Hospital · TRHospital Israelita Albert Einstein · BRImperial College London Diabetes Centre · AEIndia Diabetes Research Foundation · INJohns Hopkins University · USKarolinska University Hospital · SELjubljana University Medical Centre · SIMashhad University of Medical Sciences · IRMedical University of Lodz · PLMinistry of Health · OMMohammed Bin Rashid University of Medicine and Health Sciences · AEMultiMedica · ITSemmelweis University · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity, type 2 diabetes (T2DM), hypertension (HTN), and Cardiovascular Disease (CVD) often cluster together as "Cardiometabolic Disease" (CMD). Just under 50% of patients with CMD increased the risk of morbidity and mortality right from the beginning of the COVID-19 pandemic as it has been reported in most countries affected by the SARS-CoV2 virus. One of the pathophysiological hallmarks of COVID-19 is the overactivation of the immune system with a prominent IL-6 response, resulting in severe and systemic damage involving also cytokines such as IL2, IL4, IL8, IL10, and interferon-gamma were considered strong predictors of COVID-19 severity. Thus, in this mini-review, we try to describe the inflammatory state, the alteration of the adipokine profile, and cytokine production in the obese state of infected and not infected patients by SARS-CoV2 with the final aim to find possible influences of COVID-19 on CMD and CVD. The immunological-based discussion of the molecular processes could inspire the study of promising targets for managing CMD patients and its complications during COVID-19.

Indexed as

Cardiovascular DiseasesCOVID-19Diabetes Mellitus, Type 2AdipokinesCytokinesHumansInterferon-gammaInterleukin-10Interleukin-2Interleukin-4Interleukin-6Interleukin-8ObesityPandemicsRNA, ViralSARS-CoV-2AdipokinesCytokinesInterferon-gammaInterleukin-10Interleukin-2Interleukin-4Interleukin-6Interleukin-8RNA, ViralCardiometabolicCOVIDDiabetesInflammationMolecular

Identifiers

PMID36174875
PMCPMC9510069
OpenAlexW4297201348

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.